Novasep, a supplier of services and technologies for the life sciences industry, and Sartorius Stedim Biotech, a subgroup of the life science company Sartorius, announced the completion as of February 7, 2022, of the sale of Novasep’s chromatography equipment division to Sartorius, further to all relevant regulatory approvals having been obtained.
Novasep’s chromatography equipment division comprises resin-based batch and intensified chromatography systems, and focuses on low & high pressure for small and large molecules such as monoclonal antibodies, oligonucleotides, peptides and insulin. The business acquired generated sales of around 40 million euros in 2020 at a double-digit profit margin; final figures for 2021 are not yet available. The majority of the approximately 100 employees concerned work mainly on Novasep’s Pompey site in eastern France and some in the USA, China and India.
Since 2018, Novasep and Sartorius have been collaborating in the joint development of an optimized membrane-based, low-pressure chromatography system that processes larger molecules more productively.
This transaction is a major step for the development of the equipment business worldwide, based on the long-term expertise of Novasep’s employees and Sartorius’ strong position on this market segment.
“This achievement strengthens our relationship with the Sartorius team and represents a great opportunity for the chromatography equipment business to fully deliver its potential and accelerate its growth under this new ownership”, says Dr. Michel Spagnol, President & CEO of Novasep. “Furthermore, this announcement is aligned with Novasep’s current strategy, which is to prioritize its core business on API CDMO services for the pharmaceutical market.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!